Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia
- Author(s)
- Chua, CC; Hammond, D; Kent, A; Tiong, IS; Konopleva, MY; Pollyea, DA; DiNardo, CD; Wei, AH;
- Journal Title
- Blood Advances
- Publication Type
- epub ahead of print
- Abstract
- The clinical benefit of adding venetoclax (VEN) to hypomethylating agents or low dose cytarabine in older and/or unfit patients with newly diagnosed acute myeloid leukemia (AML) has been confirmed in phase 3 studies. With the increased uptake of VEN-based therapies for patients with AML, a pertinent question is whether treatment can be safely ceased among patients who have achieved sustained remission. We hypothesized that a proportion of patients opting to cease therapy may benefit from a treatment-free remission (TFR) period without indefinite treatment. We report the retrospective outcomes of 29 patients in remission for a minimum of 12 months on VEN-based therapy, with 55% continuing therapy (CONT) until disease progression and the 45% electively ceasing treatment (STOP). With follow up exceeding 5 years, we observed a median TFR lasting 45.8 months among the STOP cohort, with >50% of patients still in sustained remission at the data cut-off. The risk of relapse and duration of relapse-free and overall survival were similar between the two cohorts. Factors favoring sustained TFR within the cohort included NPM1 and/or IDH2 mutation at diagnosis, complete remission without measurable residual disease, and at least 12 months of VEN-based combination therapy prior to treatment cessation.
- Publisher
- ASH
- Research Division(s)
- Blood Cells And Blood Cancer
- PubMed ID
- 35511730
- Publisher's Version
- https://doi.org/10.1182/bloodadvances.2022007083
- Open Access at Publisher's Site
https://doi.org/10.1182/bloodadvances.2022007083- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2022-05-11 10:40:07
Last Modified: 2022-05-11 11:09:02